McWhirter, Sarah M.

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 1,560

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine

Immunotherapy and Immune Responsesinterferon and immune responses

Cited by 720

The host STING pathway at the interface of cancer and immunity

Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 487

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2018) · Cell Reports

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 451

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Meric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., et al. (2022) · Clinical Cancer Research

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 418

SLC19A1 transports immunoreactive cyclic dinucleotides.

Luteijn, R. D., Zaver, S. A., Gowen, B. G., Wyman, S. K., Garelis, N. E., Onia, L., McWhirter, S. M., Katibah, G. E., Corn, J. E., Woodward, J. J., et al. (2019) · Nature

interferon and immune responsesDrug Transport and Resistance Mechanisms

Cited by 379

NK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists

Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H. (2020) · Science Immunology

Immune Cell Function and Interactioninterferon and immune responses

Cited by 268

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2019) · Cell Reports

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 53